Cybin Inc. (NASDAQ:HELP – Get Free Report) saw unusually-strong trading volume on Monday. 7,874,852 shares were traded during mid-day trading, an increase of 503% from the average daily volume of 1,306,700 shares. The stock last traded at $7.3410 and had previously closed at $8.87.
Wall Street Analyst Weigh In
Several analysts have weighed in on the stock. Barclays initiated coverage on shares of Cybin in a research note on Friday, September 18th. They issued an “overweight” rating and a $35.00 price target for the company. Wells Fargo & Company raised their price objective on Cybin from $16.00 to $22.00 and gave the company an “overweight” rating in a research note on Thursday, October 22nd. Wall Street Zen downgraded Cybin from a “sell” rating to a “strong sell” rating in a report on Saturday, November 7th. Finally, TD Cowen boosted their target price on Cybin from $8.00 to $62.00 and gave the company a “buy” rating in a research note on Thursday, August 20th. Six equities research analysts have rated the stock with a Buy rating. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $47.33.
Cybin Stock Down 11.2%
The stock has a market cap of $628.82 million, a P/E ratio of -2.61 and a beta of 0.64. The firm’s fifty day moving average price is $11.24 and its 200-day moving average price is $7.81.
Cybin (NASDAQ:HELP – Get Free Report) last posted its quarterly earnings results on Friday, November 13th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.74). Sell-side analysts predict that Cybin Inc. will post -2.95 earnings per share for the current year.
Insider Activity
In other news, CEO Michael Halstead bought 100,000 shares of the company’s stock in a transaction dated Monday, September 21st. The stock was bought at an average cost of $13.47 per share, for a total transaction of $1,347,000.00. Following the completion of the acquisition, the chief executive officer owned 168,568 shares in the company, valued at approximately $2,270,610.96. This trade represents a 145.84% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Eric H. L. So purchased 100,000 shares of Cybin stock in a transaction that occurred on Tuesday, September 8th. The shares were acquired at an average price of $12.39 per share, for a total transaction of $1,239,000.00. Following the acquisition, the insider owned 4,465,014 shares in the company, valued at $55,321,523.46. This trade represents a 2.29% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders have purchased 688,000 shares of company stock valued at $8,422,830. Company insiders own 15.00% of the company’s stock.
Hedge Funds Weigh In On Cybin
Several hedge funds have recently made changes to their positions in HELP. WealthPlan Investment Management LLC bought a new position in shares of Cybin during the third quarter valued at approximately $1,272,000. Pale Fire Capital SE bought a new stake in Cybin in the second quarter valued at $1,015,000. Farther Finance Advisors LLC boosted its holdings in Cybin by 927.4% in the third quarter. Farther Finance Advisors LLC now owns 22,818 shares of the company’s stock valued at $280,000 after acquiring an additional 20,597 shares in the last quarter. AXQ Capital LP purchased a new position in Cybin during the 2nd quarter valued at $75,000. Finally, Blue Owl Capital Holdings LP increased its position in Cybin by 381.2% during the 3rd quarter. Blue Owl Capital Holdings LP now owns 288,282 shares of the company’s stock valued at $3,543,000 after purchasing an additional 228,371 shares during the period. 17.94% of the stock is owned by hedge funds and other institutional investors.
About Cybin
Cybin, which changed its name to Helus Pharma, is a clinical-stage biopharmaceutical company developing psychedelic-based treatments for mental health conditions. Its research focuses on designing and evaluating investigational compounds intended to address conditions including depression and anxiety disorders. The company’s pipeline has included CYB003, a deuterated psilocin analog being studied for major depressive disorder, and CYB004, an investigational DMT-based treatment studied for generalized anxiety disorder.
Featured Articles
- Five stocks we like better than Cybin
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
- Embraer’s Record Backlog Looks Promising, But Can It Keep Its Margins Climbing?
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.
